HealthRX.com · Printable lab tracker
After the last Mounjaro injection: glucose, HbA1c, blood pressure and weight tracker
Write down your last injection and the plan you agreed, then track fasting glucose and weight at weeks 4, 8 and 12 after stopping, with HbA1c at week 12, as the page suggests, and blood pressure alongside them. The facts box keeps what the label and the SURMOUNT-4 analyses say about timing and rebound.
The stop plan
Reason for stoppinggoal reached, side effects, cost, pregnancy plans, surgery, other
Date and dose of the last injection
Weight before Mounjaro, and at the last dose
Diabetes medicines continuing or starting
Who reviews my results, and when
What result would mean restarting or changing treatment
Readings after the last dose
| Week after last dose | Date | Fasting glucose | HbA1c | Blood pressure | Weight | Hunger or symptoms |
|---|---|---|---|---|---|---|
| 4 | ||||||
| 8 | ||||||
| 12 | ||||||
What the sources say
- Tirzepatide's elimination half-life is about 5 days.[1]
- One missed dose can be taken within 4 days (96 hours); after that, skip it and keep to your regular day.[1]
- In a SURMOUNT-4 analysis of adults without diabetes, HbA1c rose by 0.14 to 0.35 points and systolic blood pressure by 6.8 to 10.4 mm Hg in the year after tirzepatide was switched to placebo, more where more weight returned.[2]
- Tell your healthcare provider if you become pregnant while using Mounjaro.[1]
Questions before the last dose
- Which glucose or HbA1c result should prompt a call or a change of plan?
- Do I need another diabetes medicine started before or after stopping?
- Should I step down through lower doses or stop at once, and why?
- If I restart later, which dose would I restart at?
- Will my insurer need a new prior authorization if I restart?
Sources for the facts on this sheet
- Eli Lilly and Company, via DailyMed. Mounjaro (tirzepatide) injection, for subcutaneous use: prescribing information and Medication Guide. Effective 2026-08-27. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
- Horn DB, Linetzky B, Davies MJ, et al. Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial. JAMA Intern Med 2026. PMID 41284285. https://pubmed.ncbi.nlm.nih.gov/41284285/
This sheet records information for a conversation with your prescriber or pharmacist. It does not replace their instructions or the medication's prescribing information.